Scilex Holding (SCLX) Cash & Equivalents Growth (1y) (2021 - 2026)
Scilex Holding (SCLX) Cash & Equivalents Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash & Equiv. Growth (1y) (Qtr) |
| 1 |
Gsk |
93,162,528.78 Bn |
93,162,523.82 Bn |
7.76 Bn |
-17.47% |
| 2 |
Eli Lilly |
1,017.87 Bn |
1,012.58 Bn |
16.22 Bn |
70.76% |
| 3 |
Johnson & Johnson |
575.51 Bn |
553.46 Bn |
15.96 Bn |
-43.63% |
| 4 |
AbbVie |
400.43 Bn |
391.08 Bn |
10.78 Bn |
81.47% |
| 5 |
Merck |
294.19 Bn |
288.54 Bn |
12.09 Bn |
-38.27% |
| 6 |
Amgen |
182.41 Bn |
170.37 Bn |
5.87 Bn |
36.64% |
| 7 |
Gilead Sciences |
150.97 Bn |
143.24 Bn |
5.52 Bn |
-3.76% |
| 8 |
Pfizer |
145.75 Bn |
132.97 Bn |
-1.21 Bn |
19.09% |
| 9 |
Bristol Myers Squibb |
113.35 Bn |
102.90 Bn |
8.07 Bn |
-11.96% |
| 10 |
Scilex Holding |
57.99 Mn |
-91.94 Mn |
4.15 Mn |
2,397.81% |
| Date | Value |
|---|
| Mar 31, 2026 |
2,397.81% |
| Dec 31, 2025 |
51.44% |
| Sep 30, 2025 |
1,068.83% |
| Jun 30, 2025 |
-40.48% |
| Mar 31, 2025 |
219.03% |
| Dec 31, 2024 |
-16.55% |
| Sep 30, 2024 |
-96.15% |
| Jun 30, 2024 |
-79.81% |
| Mar 31, 2024 |
-64.35% |
| Dec 31, 2023 |
79.53% |
| Sep 30, 2023 |
5,620.66% |
| Jun 30, 2023 |
9,613.84% |
| Mar 31, 2023 |
3,901.88% |
| Dec 31, 2022 |
-49.65% |
| Sep 30, 2022 |
-69.77% |
| Jun 30, 2022 |
36.35% |
| Mar 31, 2022 |
-59.53% |
| Dec 31, 2021 |
14,117.82% |
| Sep 30, 2021 |
46.63% |
